OncoTargets and therapy最新文献_第3页

G-Protein-Signaling Modulator 2 Expression and Role in a CD133⁺ Pancreatic Cancer Stem Cell Subset [Retraction]. G 蛋白信号调节器 2 在 CD133+ 胰腺癌干细胞亚群中的表达和作用 [撤回]。

IF 2.7 4区医学

OncoTargets and therapy Pub Date : 2024-08-14 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S491280

引用次数: 0

circHIPK₃ Promotes Cell Proliferation and Migration of Gastric Cancer by Sponging miR-107 and Regulating BDNF Expression [Retraction]. circHIPK3 通过疏导 miR-107 和调控 BDNF 表达促进胃癌细胞增殖和迁移 [撤回]。

IF 2.7 4区医学

OncoTargets and therapy Pub Date : 2024-08-14 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S491282

引用次数: 0

Combination of Sintilimab and Anlotinib for Metastatic Osteosarcoma: A Case Report. 辛替利单抗和安罗替尼联合治疗转移性骨肉瘤：病例报告

IF 2.7 4区医学

OncoTargets and therapy Pub Date : 2024-08-13 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S464678

Gaoyan Tang, Qianqian Zhang, Fengxia Wang, Hua Zhang, Yuanling Qi

引用次数: 0

Icariin Mitigates the Growth and Invasion Ability of Human Oral Squamous Cell Carcinoma via Inhibiting Toll-Like Receptor 4 and Phosphorylation of NF-κB P65 [Retraction] 淫羊藿苷通过抑制Toll-Like Receptor 4和NF-κB P65磷酸化减轻人口腔鳞状细胞癌的生长和侵袭能力 [撤回]

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-08-08 DOI: 10.2147/ott.s490273

Ke Lei, Bing Ma, Ping Shi, Che Jin, Tan Ling, Longjiang Li, Xiangyi He, Lunchang Wang

引用次数: 0

MiR-181c-5p Mitigates Tumorigenesis in Cervical Squamous Cell Carcinoma via Targeting Glycogen Synthase Kinase 3β Interaction Protein (GSKIP) [Retraction] MiR-181c-5p通过靶向糖原合成酶激酶3β相互作用蛋白（GSKIP）缓解宫颈鳞状细胞癌的肿瘤发生 [撤稿］

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-08-08 DOI: 10.2147/ott.s490276

Niuniu Li, Chun Cheng, Tieyan Wang

引用次数: 0

Down-Regulation of ZEB1 by miR-199a-3p Overexpression Restrains Tumor Stem-Like Properties and Mitochondrial Function of Non-Small Cell Lung Cancer [Retraction] miR-199a-3p过表达对ZEB1的下调抑制了非小细胞肺癌的肿瘤干样特性和线粒体功能 [撤稿］

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-08-07 DOI: 10.2147/ott.s490275

Juan Bai, Wen-Yu Jiao

引用次数: 0

The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer. 阿帕替尼和安罗替尼治疗晚期非小细胞肺癌的有效性和安全性

IF 2.7 4区医学

OncoTargets and therapy Pub Date : 2024-08-06 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S468932

Xiao Wei, Yun Zhao, Wenyue Yan, Qigang Dai, Hui Wu, Yang Miao, Lei Huang, Qing Liu, Xuyao Zhang, Hongxia Wang, Yanan Liu, Linlin Zhang

{"title":"The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer.","authors":"Xiao Wei, Yun Zhao, Wenyue Yan, Qigang Dai, Hui Wu, Yang Miao, Lei Huang, Qing Liu, Xuyao Zhang, Hongxia Wang, Yanan Liu, Linlin Zhang","doi":"10.2147/OTT.S468932","DOIUrl":"10.2147/OTT.S468932","url":null,"abstract":"Background: Anlotinib and apatinib, both vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), are clinically established in the treatment of advanced non-small cell lung cancer (NSCLC) in China, with anlotinib emerging as a standard treatment strategy. This study was conducted to evaluate the efficacy and safety of apatinib and anlotinib, and to compare their differences in treating patients with advanced NSCLC.Patients and methods: We retrospectively analyzed the data of patients with advanced NSCLC treated with apatinib or anlotinib at a hospital in Eastern China from January 2017 to December 2021. The primary endpoint was progression-free survival (PFS), while secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety profile.Results: A total of 145 patients were included in this study. Median PFS (mPFS) was 3.53 months for the apatinib group and 5.3 months for the anlotinib group (HR = 0.59, 95% CI: 0.41-0.84; P = 0.004), and median OS (mOS) was 7.6 months versus 15.6 months (HR = 0.68, 95% CI: 0.46-1.00; P = 0.048), which all showed significant differences after adjusting for confounders (P < 0.05). Subgroup analysis revealed that the presence or absence of bone metastases significantly influenced PFS in both treatment groups. The ORR was 3.03% in the anlotinib group versus 10.13% in the apatinib group (P = 0.12), the DCR was 72.73% versus 51.90% (P = 0.21). No unanticipated adverse events (AEs) were observed. The incidence of grade 3-4 AEs was significantly higher in the apatinib group (31.65% vs 13.64%, P < 0.05).Conclusion: Anlotinib demonstrated greater efficacy and safety compared to apatinib in the treatment of advanced NSCLC, particularly in patients with bone metastases and EGFR(-).","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11316477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Function and Therapeutic Potential of Non-Coding RNA in Ameloblastoma. 非编码 RNA 在母细胞瘤中的功能和治疗潜力

IF 2.7 4区医学

OncoTargets and therapy Pub Date : 2024-08-06 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S474038

Xu Huang, Feihan Gu, Mingyu Zhao, Wenkai Huang, Wenjia Han, Ran Chen, Yuanyin Wang

{"title":"Function and Therapeutic Potential of Non-Coding RNA in Ameloblastoma.","authors":"Xu Huang, Feihan Gu, Mingyu Zhao, Wenkai Huang, Wenjia Han, Ran Chen, Yuanyin Wang","doi":"10.2147/OTT.S474038","DOIUrl":"10.2147/OTT.S474038","url":null,"abstract":"Ameloblastoma (AB) is a common odontogenic tumor that develops in the mouth. Despite its benign nature, AB exhibits significant invasiveness leading to tumor metastasis and high postoperative recurrence rates. Studies have shown a relationship between the occurrence and development of various tumors and non-coding RNA (ncRNA). NcRNA, transcribed from the genomes of mammals and other complex organisms, are often products of alternative splicing and processing into smaller products. MicroRNA (miRNA), circular RNA (circRNA), and long non-coding RNA (lncRNA) are the main types of ncRNA. NcRNA play increasingly significant roles in the pathogenesis of human cancers, regulating their occurrence and progression as oncogenes or tumor suppressors. They are involved in tumor development and progression through alternative splicing of pre-mRNA, transcriptional regulation, mRNA stability, protein translation, and chromatin remodeling and modification. The importance of ncRNA in AB has received significant attention in recent years. However, the biological functions and mechanisms of ncRNA in AB remain largely unknown. In this review, we not only explore the functions and roles of ncRNA in AB, but also describe and envision their potential functional roles as biomarkers in AB diagnosis. In particular, we highlight the potential of miR-29a as a molecular marker for diagnosis and therapy. As promising novel therapeutic targets, the biological functions of ncRNA need further study, which is indispensable.","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11316470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nrf2-Mediated Antioxidant Response and Drug Efflux Transporters Upregulation as Possible Mechanisms of Resistance in Photodynamic Therapy of Cancers. Nrf2介导的抗氧化反应和药物外排转运体上调可能是癌症光动力疗法产生抗药性的机制

IF 2.7 4区医学

OncoTargets and therapy Pub Date : 2024-08-05 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S457749

Olawale Razaq Ajuwon, Fleury Augustine Nsole-Biteghe, Jean Delacroix Ndong, Lester Merlin Davids, Basiru Olaitan Ajiboye, Bartholomew Brai, Fisayo Abraham Bamisaye, John Adeolu Falode, Ikenna Maximillian Odoh, Kabirat Iyabode Adegbite, Bosede Oluwasayo Adegoke, Monde Ntwasa, Sogolo Lucky Lebelo, Ademola Olabode Ayeleso

{"title":"Nrf2-Mediated Antioxidant Response and Drug Efflux Transporters Upregulation as Possible Mechanisms of Resistance in Photodynamic Therapy of Cancers.","authors":"Olawale Razaq Ajuwon, Fleury Augustine Nsole-Biteghe, Jean Delacroix Ndong, Lester Merlin Davids, Basiru Olaitan Ajiboye, Bartholomew Brai, Fisayo Abraham Bamisaye, John Adeolu Falode, Ikenna Maximillian Odoh, Kabirat Iyabode Adegbite, Bosede Oluwasayo Adegoke, Monde Ntwasa, Sogolo Lucky Lebelo, Ademola Olabode Ayeleso","doi":"10.2147/OTT.S457749","DOIUrl":"10.2147/OTT.S457749","url":null,"abstract":"Photodynamic therapy (PDT) is a groundbreaking approach involving the induction of cytotoxic reactive oxygen species (ROS) within tumors through visible light activation of photosensitizers (PS) in the presence of molecular oxygen. This innovative therapy has demonstrated success in treating various cancers. While PDT proves highly effective in most solid tumors, there are indications that certain cancers exhibit resistance, and some initially responsive cancers may develop intrinsic or acquired resistance to PDT. The molecular mechanisms underlying this resistance are not fully understood. Recent evidence suggests that, akin to other traditional cancer treatments, the activation of survival pathways, such as the KEAP1/Nrf2 signaling pathway, is emerging as an important mechanism of post-PDT resistance in many cancers. This article explores the dual role of Nrf2, highlighting evidence linking aberrant Nrf2 expression to treatment resistance across a range of cancers. Additionally, it delves into the specific role of Nrf2 in the context of photodynamic therapy for cancers, emphasizing evidence that suggests Nrf2-mediated upregulation of antioxidant responses and induction of drug efflux transporters are potential mechanisms of resistance to PDT in diverse cancer types. Therefore, understanding the specific role(s) of Nrf2 in PDT resistance may pave the way for the development of more effective cancer treatments using PDT.","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11313505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long Noncoding RNA UCA1 Targets miR-582-5p and Contributes to the Progression and Drug Resistance of Bladder Cancer Cells Through ATG7-Mediated Autophagy Inhibition [Retraction] 长非编码 RNA UCA1 靶向 miR-582-5p，通过 ATG7 介导的自噬抑制作用促进膀胱癌细胞的进展和耐药性 [撤回论文］

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-07-25 DOI: 10.2147/ott.s488460

Junfeng Wu, Wei Li, Jinzhuo Ning, Weimin Yu, Ting Rao, Fan Cheng

引用次数: 0